Nanollose Ltd. (AU:NC6)
ASX:NC6
Top Page
Nanollose Ltd.
(Sydney:NC6)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.06
▲(24.00% Upside)
Action:ReiteratedDate:03/04/26
The score is weighed down primarily by weak financial performance (persistent losses, zero revenue in FY2025, and ongoing cash burn implying higher financing risk). Technicals are modestly positive (positive MACD and price above key longer-term averages), but valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Low leverage / limited debt
Low absolute debt levels provide durable financial flexibility, reducing near-term refinancing risk and giving management runway to prioritise product development and commercialisation. This buffer supports operations during continued R&D and helps preserve optionality for strategic partnerships or scaling if revenue traction improves.
Negative Factors
Persistent losses and zero revenue
Sustained losses combined with revenue falling to zero undermine proof of commercial traction and place the business on a financing-dependent path. Without recurring revenue, operating losses will likely persist, forcing access to external capital and raising execution risk for commercial roll-out and scaling over the next 2-6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / limited debt
Low absolute debt levels provide durable financial flexibility, reducing near-term refinancing risk and giving management runway to prioritise product development and commercialisation. This buffer supports operations during continued R&D and helps preserve optionality for strategic partnerships or scaling if revenue traction improves.
Read all positive factors
Nanollose Ltd. (NC6) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$20.61M
Dividend YieldN/A
Average Volume (3M)138.71K
Price to Earnings (P/E)―
Beta (1Y)-0.03
Revenue Growth-100.00%
EPS Growth2.86%
CountryAU
EmployeesN/A
SectorConsumer Cyclical
Sector Strength84
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding327,066,350
10 Day Avg. Volume179,263
30 Day Avg. Volume138,709
Financial Highlights & Ratios
PEG Ratio2.33
Price to Book (P/B)34.86
Price to Sales (P/S)0.00
P/FCF Ratio-12.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nanollose Ltd. Business Overview & Revenue Model
Company Description
Nanollose Limited, a biomaterials company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. The company offers Nullarbor Fibre, a tree-free Nullarbor lyocell fibre; and Jelli Grow, an a...
How the Company Makes Money
null...
Nanollose Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 12.50K | 412.16K | 224.61K | 322.86K |
| Gross Profit | -33.11K | -35.83K | -779.20K | 58.29K | -223.55K | -70.57K |
| EBITDA | -2.41M | -1.59M | -1.10M | -1.16M | -1.51M | -873.73K |
| Net Income | -2.23M | -1.43M | -1.16M | -1.35M | -1.57M | -931.04K |
Balance Sheet | ||||||
| Total Assets | 434.76K | 747.79K | 241.95K | 633.24K | 1.91M | 3.38M |
| Cash, Cash Equivalents and Short-Term Investments | 274.97K | 617.32K | 138.75K | 548.25K | 1.59M | 3.01M |
| Total Debt | 250.21K | 13.09K | 42.53K | 11.52K | 38.09K | 37.88K |
| Total Liabilities | 604.51K | 351.38K | 465.64K | 181.61K | 181.51K | 507.83K |
| Stockholders Equity | -169.75K | 396.41K | -223.69K | 451.63K | 1.73M | 2.87M |
Cash Flow | ||||||
| Free Cash Flow | -1.78M | -1.10M | -900.95K | -1.01M | -1.39M | -1.01M |
| Operating Cash Flow | -1.78M | -1.10M | -900.95K | -1.01M | -1.38M | -935.19K |
| Investing Cash Flow | 0.00 | 0.00 | 15.97K | 0.00 | -5.35K | -272.15K |
| Financing Cash Flow | 1.65M | 1.58M | 475.49K | -26.57K | -32.69K | 3.37M |
Nanollose Ltd. Technical Analysis
Negative
0.05
Price Trends
0.07
Negative
0.06
Positive
0.06
Negative
Market Momentum
>-0.01
Positive
29.78
Positive
30.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NC6, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 29.78 is Positive, neither overbought nor oversold. The STOCH value of 30.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NC6.
Nanollose Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
48 Neutral | AU$13.12M | -1.00 | -218.76% | ― | ― | ― | |
47 Neutral | AU$20.61M | -2.45 | -1964.93% | ― | -100.00% | 2.86% | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
42 Neutral | AU$55.73M | -5.28 | -62.49% | ― | ― | 10.78% | |
42 Neutral | AU$84.50M | -14.80 | -40.65% | ― | 700.00% | 26.88% | |
40 Underperform | AU$35.68M | -10.60 | -142.30% | ― | 110.44% | 35.90% |
* Consumer Cyclical Sector Average
AU:NC6
Nanollose Ltd.
0.06
0.02
57.50%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
12.77%
AU:ADO
AnteoTech Ltd
0.01
0.00
0.00%
AU:CMB
Regeneus Ltd.
0.48
0.18
57.38%
AU:1AD
AdAlta Ltd.
―
―
―
AU:ALA
Arovella Therapeutics Limited
0.07
>-0.01
-12.50%
Nanollose Ltd. Corporate Events
Nanollose Director Resigns as Board Reviews Composition for Next Growth Phase
Mar 15, 2026
Nanollose has announced the resignation of non-executive director Heidi Beatty, effective 1 April 2026, after seven years on the board during which she contributed industry expertise and a strong focus on sustainable innovation. Beatty is stepping...
Nanollose Seeks ASX Quotation for 580,000 New Shares
Mar 13, 2026
Nanollose Limited has applied to the ASX for quotation of 580,000 new ordinary fully paid shares under its code NC6. The new securities, issued on March 13, 2026, modestly expand the company’s quoted share capital and may marginally affect e...
Nanollose Seeks ASX Quotation for 2,000 New Ordinary Shares
Mar 4, 2026
Nanollose Limited has applied to the ASX for quotation of 2,000 new fully paid ordinary shares under its ticker NC6. The shares, issued on 4 March 2026 following the exercise or conversion of existing options or other convertible securities, repre...
Nanollose Loss Widens as Pre-Revenue Development Phase Continues
Feb 27, 2026
Nanollose Limited reported a sharp widening of its half-year loss to $1,526,079 for the period ended 31 December 2025, more than doubling the prior corresponding period’s loss of $725,681, while revenue from ordinary activities remained at z...
Nanollose Boosts Cash Reserves With $311,000 R&D Tax Rebate
Feb 26, 2026
Nanollose Limited, an ASX-listed biomaterials company, develops sustainable fibres, fabrics and novel materials using tree-free cellulose produced via fermentation of agricultural waste and by-products. Its portfolio includes Nullarbor fibres, Mic...
Nanollose Seeks ASX Quotation for Additional Ordinary Shares
Feb 25, 2026
Nanollose Ltd. has lodged an application with the ASX for quotation of 1,667 new ordinary fully paid shares under its NC6 ticker. The modest issuance, arising from the exercise or conversion of existing securities, marginally increases the company...
Nanollose Advances Largest Nullarbor™ Pilot Spin and Bolsters IP as It Shifts Focus to Scale and Cost
Jan 30, 2026
Nanollose reported that the December 2025 quarter marked a transition from validating small pilot batches to focusing on scalability and cost reduction for its Nullarbor™ forest-friendly lyocell fibre. The company advanced preparations for a...
Nanollose Seeks ASX Quotation for Additional Ordinary Shares
Jan 23, 2026
Nanollose Limited has applied to the ASX for quotation of 15,067 new fully paid ordinary shares under its existing ticker, NC6. The additional shares, issued on 23 January 2026 following the exercise or conversion of existing securities, will mode...
Nanollose Expands Global Patent Footprint to Bolster Fashion and Vertical Farming Push
Jan 21, 2026
Nanollose has strengthened its intellectual property portfolio with new patent grants in Japan, Canada and South Korea covering its Nullarbor™ lyocell fibre process, viscose fibre production from microbial cellulose, and its original JelliGr...
Nanollose Options Lapse, Simplifying Capital Structure
Jan 21, 2026
Nanollose Ltd., listed on the ASX under code NC6, has reported the expiry of 500,000 listed options (NC6AS) exercisable at $0.10 that lapsed unexercised on 20 January 2026, leading to a minor change in the composition of its issued capital. The ce...
Nanollose Ships Upgraded Microbial Cellulose for Largest Nullarbor Pilot Spin with Birla Cellulose
Jan 4, 2026
Nanollose has delivered a 200kg upgraded batch of microbial cellulose feedstock to co-development partner Birla Cellulose’s pilot facility in India for a fourth pilot production spin of its proprietary Nullarbor fibre. Produced by China-base...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.